Phase I dose-escalation trial of AMXT 1501 dicaprate plus difluoromethylornithine: a dual-agent approach targeting immunosuppressive polyamine metabolism.

AMXT 1501 - Aminex Therap

http://www.ncbi.nlm.nih.gov/pubmed/40913836

A I Spira; A L Vandross; A W Tolcher; M R BURNS; S A Piha-Paul

Sep 8, 2025